Similar articles for PMID: 23903238

Year	Number of Results
1974	1
1981	1
1989	1
1993	2
1995	1
1997	2
1998	1
2000	1
2001	1
2002	4
2003	2
2004	4
2005	5
2006	3
2007	5
2008	4
2009	4
2010	11
2011	17
2012	11
2013	8
2014	12
2015	7
2016	9
2017	7
2018	1
2019	3
2020	10
2021	4
2022	2
2023	2
2024	0

1

The management of immunosuppression in patients with inflammatory bowel disease and cancer.

Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. Bernheim O, et al. Gut. 2013 Nov;62(11):1523-8. doi: 10.1136/gutjnl-2013-305300. Epub 2013 Jul 31. Gut. 2013. PMID: 23903238 Review. No abstract available.

2

Managing immunosuppression in medical patients.

Pritchard CW, Hawthorne AB. Pritchard CW, et al. Br J Hosp Med (Lond). 2009 Jul;70(7):394-8. doi: 10.12968/hmed.2009.70.7.43122. Br J Hosp Med (Lond). 2009. PMID: 19584781 Review.

3

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M. Caprilli R, et al. Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013. Dig Liver Dis. 2005. PMID: 15893279 Review.

4

Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation.

El-Nachef N, Terdiman J, Mahadevan U. El-Nachef N, et al. Am J Gastroenterol. 2010 May;105(5):1210-1. doi: 10.1038/ajg.2010.33. Am J Gastroenterol. 2010. PMID: 20445523 No abstract available.

5

Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting.

van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, Lémann M, Ansari A, Almer SH, Florin TH, Gearry RB, Mulder CJ, Mantzaris G, van Bodegraven AA; Thiopurine Task Force Interest Group. van Asseldonk DP, et al. Dig Liver Dis. 2011 Apr;43(4):270-6. doi: 10.1016/j.dld.2010.09.001. Epub 2010 Oct 8. Dig Liver Dis. 2011. PMID: 20934926 Review.

6

Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.

Marzano AV, Borghi A, Meroni PL, Crosti C, Cugno M. Marzano AV, et al. Autoimmunity. 2014 May;47(3):146-53. doi: 10.3109/08916934.2013.873414. Epub 2014 Jan 20. Autoimmunity. 2014. PMID: 24437626 Review.

7

[Inflammatory bowel diseases].

Felley C, Guyot J, Hess J, Mottet C, Delarive J, Michetti P. Felley C, et al. Rev Med Suisse. 2005 Jan 19;1(3):218-20, 223-7. Rev Med Suisse. 2005. PMID: 15770816 Review. French.

8

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Hanauer SB. Hanauer SB. Gut. 2007 Sep;56(9):1181-3. doi: 10.1136/gut.2006.115980. Gut. 2007. PMID: 17698862 Free PMC article.

9

State-of-the-art: Immunosuppression and biologic therapy.

Sandborn WJ. Sandborn WJ. Dig Dis. 2010;28(3):536-42. doi: 10.1159/000320413. Epub 2010 Sep 30. Dig Dis. 2010. PMID: 20926883 Review.

10

Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

Rutgeerts P, Van Assche G, Vermeire S. Rutgeerts P, et al. Aliment Pharmacol Ther. 2006 Feb 15;23(4):451-63. doi: 10.1111/j.1365-2036.2006.02786.x. Aliment Pharmacol Ther. 2006. PMID: 16441465 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

128 results

Results by year